You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Metastatic Disease Considerations in HER2-Positive Breast Cancer

  • Authors: Reshma L. Mahtani, DO; Alberto Montero, MD, MBA; Paolo Tarantino, MD; A. Jo Chien, MD; Allison Butts, PharmD, BCOP; Jennifer McKenna, RN, MSN, AOCNP
  • CME / ABIM MOC / CE Released: 12/1/2022
  • Valid for credit through: 12/1/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

    IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners, physicians assistants, pharmacists, and nurses.

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data associated with emerging HER2-directed antibody-drug conjugates for the treatment of HER2-positive breast cancer
    • Emerging novel therapies for the treatment of HER2-positive breast cancer
  • Have greater competence related to
    • Selecting the appropriate treatments for patients with metastatic HER2-positive breast cancer
    • Managing toxicities associated with therapies used in HER2-positive breast cancer
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into breast cancer care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Reshma L. Mahtani, DO

    Chief of Breast Medical Oncology
    Miami Cancer Institute
    Baptist Health South Florida
    Plantation, Florida

    Disclosures

    Reshma L. Mahtani, DO, has the following relevant financial relationships:
    Consultant or advisor for: Agendia; Amgen; AstraZeneca; Biotheranostics; Daiichi Sankyo; Eisai; Genentech; Gilead; Lilly; Merck; Novartis; Pfizer; PUMA; Sanofi; Seagen, Inc.
    Research funding from: Agendia; AstraZeneca; Genentech; Veru

  • Alberto Montero, MD, MBA

    Professor of Medicine
    University Hospitals Seidman Cancer Center
    Case Western Reserve University
    Cleveland, Ohio

    Disclosures

    Alberto Montero, MD, MBA, has the following relevant financial relationships:
    Consultant or advisor for: Agendia; Welwaze
    Speaker or member of speakers bureau for: Agendia
    Research funding from: Genmab; Oncosec; Roche; Zymeworks
    Stock options from: CareVive

  • Paolo Tarantino, MD

    Researcher
    The European Institute of Oncology
    Milan, Italy
    Clinical Research Fellow
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Paolo Tarantino, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Daiichi Sankyo
    Speaker or member of speakers bureau for: AstraZeneca

  • A. Jo Chien, MD

    Professor of Clinical Medicine
    Breast Medical Oncology
    Helen Diller Family Comprehensive Cancer Center
    University of California San Francisco
    San Francisco, California

    Disclosures

    A. Jo Chien, MD, has the following relevant financial relationships:
    Research funding from: Amgen; Merck; PUMA; Seagen, Inc.

  • Allison Butts, PharmD, BCOP

    Clinical Coordinator-Medical Oncology
    UK HealthCare Markey Cancer Center
    Assistant Professor
    Pharmacy Practice and Science Department
    University of Kentucky
    College of Pharmacy
    Lexington, Kentucky

    Disclosures

    Allison Butts, PharmD, BCOP, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; BeyondSpring Pharmaceuticals

  • Jennifer McKenna, RN, MSN, AOCNP

    Nurse Practitioner
    Breast Oncology Center
    Dana Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Jennifer McKenna, RN, MSN, AOCNP, has no relevant financial relationships.

Editor

  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology. 

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-22-310-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Metastatic Disease Considerations in HER2-Positive Breast Cancer

Authors: Reshma L. Mahtani, DO; Alberto Montero, MD, MBA; Paolo Tarantino, MD; A. Jo Chien, MD; Allison Butts, PharmD, BCOP; Jennifer McKenna, RN, MSN, AOCNPFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/1/2022

Valid for credit through: 12/1/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Treatment Sequencing for HER2-Positive Metastatic Breast Cancer

Dr Alberto Montero discusses the latest on sequencing therapies for MBC.
Alberto Montero, MD, MBA

Emerging HER2-Directed ADCs for HER2-Positive Breast Cancer

Did you know that ADCs enable tumor-specific targeting? Learn more about ADC use in HER2-positive breast cancer.
A. Jo Chien, MD

Novel TKIs, Bispecific Antibodies, and Immunotherapy

How up to date are you on the latest data on TKIs, bispecific antibodies, and immunotherapy use in breast cancer?
Paolo Tarantino, MD

Mitigation and Management of Toxicities in HER2-Positive Breast Cancer: Nursing and Pharmacist Perspectives

Nursing and pharmacist expertise are integral aspects of care for managing patients with breast cancer. Learn more about it in this segment.
Allison Butts, PharmD, BCOP; Jennifer McKenna, RN, MSN, AOCNP
 

Educational Impact Challenge

The goal of this activity is for the learners to be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print